Abivax (ABVX) Cash from Operations (2024 - 2025)

Abivax (ABVX) recorded quarterly Cash from Operations of 27004645.5 in Q4 2025, up 67.59% quarter-over-quarter from 83333754.08 in Q3 2025, and up 24.66% on a YoY basis from 21662958.62 in Q4 2024.

Abivax (ABVX) Cash from Operations (2024 - 2025) Analysis & Trends

Abivax's Cash from Operations history runs 2 years deep, the most recent figure standing at 27004645.5 for Q4 2025.

  • In Q4 2025, Cash from Operations rose 24.66% year-over-year to 27004645.5; the TTM figure through Dec 2025 stood at 183082545.95 (down 9.79% YoY), while the FY2025 annual figure was 187527410.22, down 13.88% from the prior year.
  • Cash from Operations was 27004645.5 for Q4 2025 at Abivax, up from 83333754.08 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 27004645.5 in Q4 2025 to a low of 83333754.08 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -1.67 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -12.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -2.49 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.43 Bn
9 Abivax 91.96 Bn 91.96 Bn - -
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn 1.08 Bn

Historic Data

Download Data
DateValue
Dec 31, 2025 -27.00 Mn
Dec 31, 2025 -27.00 Mn
Sep 30, 2025 -83.33 Mn
Sep 30, 2025 -83.33 Mn
Jun 30, 2025 -37.74 Mn
Jun 30, 2025 -37.74 Mn
Mar 31, 2025 -35.00 Mn
Mar 31, 2025 -35.00 Mn
Dec 31, 2024 -35.84 Mn
Dec 31, 2024 -35.84 Mn
Sep 30, 2024 -38.86 Mn
Sep 30, 2024 -38.86 Mn
Jun 30, 2024 -54.30 Mn
Jun 30, 2024 -54.30 Mn
Mar 31, 2024 -37.76 Mn
Mar 31, 2024 -37.76 Mn